Hi Barrel, that may be true, but didn't they have an arrangement for interested parties to have access to data from the trials periodically through an arrangement with a third party, in a confidential way? If so, I would expect that it wouldn't take months after the completion of the trial to arrange a deal, because a lot of the negotiations should have already taken place. I've lost money on this company also, but not too much because I cut my losses and put my hard earned elsewhere. There's much more to a good investment than just having a good product (or in the case of Invion, IP). Too often I see with biotechs that scientists don't make good managers of companies. Finally, over the last year or so I've found great success with investing by following the smart money. It is clear that they are not interested in Invion, which makes me wonder, if the science is so sound, and the company so cheap, why aren't they in there? They were for Alchemia, and there's some in there for Neuren...
Management should be taking a zero salary to get them through to signing the partnering deal without having to issue more shares. Since they hold so many shares themselves, wouldn't this be in their best interests, and a sign of good will to long suffering shareholders.
I hope the smart money is wrong, and this gaps up massively soon!
Expand
(20min delay)